What we do
Precision Medicines is a clinical stage biotechnology company focussed on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
The development programs are focused on cancer sub types using a precision or personalised medicine approach, whereby therapies are co-developed with companion biomarkers to target the specific drivers of cancers.
A greater understanding of cancer disease mechanisms leads to tailoring treatments to the needs of individual patients using companion diagnostics, allowing medicines to be matched only to those patients that will benefit from them. Advances in science are allowing us to design novel therapies together with diagnostic tests to deliver superior outcomes to individual patients or specific groups of patients.
Growth through partnering
Precision Medicines partners with biotech, pharma, academic and clinical centres in developing cancer therapies which have evidence of significant clinical benefit in patient subsets or niche areas.